SCHEMBL16092338

SCHEMBL16092338

COC(=O)c1cc(-c2[nH]c3c(C#N)cnn3c(=O)c2C(C)C)ccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 10/20 0.38
▸ LMNA P02545 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HPGD P15428 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ KDM5B Q9UGL1 4/20 0.34
▸ KDM5C P41229 3/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ S1PR1 P21453 1/20 0.34
▸ S1PR3 Q99500 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ KDM6B O15054 1/20 0.33
▸ KDM5D Q9BY66 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16092357 0.86 KDM5A (0.40) KDM5AALDH1A1KDM5BKDM5CKDM4E
SCHEMBL16092358 0.84 GRM2 (0.43) KDM5AKDM4E
SCHEMBL16092354 0.83 KDM4E (0.41) SMN1; SMN2HPGDALDH1A1CYP1A2HSD17B10
SCHEMBL16091921 0.82 KDM5A (0.40) KDM5AALDH1A1KDM4E
SCHEMBL16092523 0.81 KDM5A (0.49) KDM5ALMNAHPGDALDH1A1KDM5B
SCHEMBL16092379 0.81 TLR7 (0.42) KDM4E
SCHEMBL16092418 0.81 AR (0.41) KDM5AKDM5BKDM5CKDM6BKDM5D
SCHEMBL16092347 0.80 KDM5A (0.40) KDM5ALMNASMN1; SMN2KDM5BKDM5C
SCHEMBL17547806 0.80 KDM5A (0.38) KDM5AS1PR1S1PR3
SCHEMBL17547826 0.80 KDM5A (0.39) KDM5AKDM5BKDM5CKDM6BKDM5D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10035801-B2 Pyrazolo compounds and uses thereof GENENTECH, INC. (US) 2018-07-31 — — US disclosed
US-10035801-B2 Pyrazolo compounds and uses thereof GENENTECH, INC. (US) 2018-07-31 — — US disclosed
US-20160060267-A1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-03-03 — — US disclosed
US-20160060267-A1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-03-03 — — US disclosed
WO-2015135094-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2015-09-17 — — WO disclosed
WO-2014139326-A1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10035801-B2 Pyrazolo compounds and uses thereof KDM5A, KDM5C, KDM5B KDM5A 1/4885LMNA 2737/4885SMN1; SMN2 1532/4885
US-20160060267-A1 PYRAZOLO COMPOUNDS AND USES THEREOF KDM5A, KDM5C, KDM5B KDM5A 1/4885LMNA 2737/4885SMN1; SMN2 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback